Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuland LaboratoriesNSE:NEULANDLAB -2.50%91 Cyclically Adjusted PB Ratio is 23.97 as of Jul. 14, 2026, which is 7% above its 10-year median of 22.44. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 91/100 and a GF Value™ of ₹16,059.40 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 759 Drug Manufacturers companies, Neuland Laboratories ranks worse than 97.63% on this metric.
The historical rank and industry rank for Neuland Laboratories's Cyclically Adjusted PB Ratio or its related term are showing as below:
NSE:NEULANDLAB'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 15.69 Med: 22.44 Max: 24.93
Current: 23.98
During the past years, Neuland Laboratories's highest Cyclically Adjusted PB Ratio was 24.93. The lowest was 15.69. And the median was 22.44.
NSE:NEULANDLAB's Cyclically Adjusted PB Ratio is ranked worse than 97.63% of 759
companies
in the Drug Manufacturers industry
Industry Median: 1.82
vs NSE:NEULANDLAB: 23.98
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Neuland Laboratories's adjusted book value per share data for the three months ended in Mar. 2026 was ₹1,461.008. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹793.29 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Neuland Laboratories (NSE:NEULANDLAB) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Neuland Laboratories Cyclically Adjusted PB Ratio Related Terms
Neuland Laboratories Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuland Laboratories Cyclically Adjusted PB Ratio Chart
NSE:NEULANDLAB vs ZTS, UTHR: Cyclically Adjusted PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's Cyclically Adjusted PB Ratio falls into.
Neuland Laboratories Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 23.97 mean?
Neuland Laboratories (NSE:NEULANDLAB) has a Cyclically Adjusted PB Ratio of 23.97 as of Jul. 14, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Neuland Laboratories and its competitors. This is near median its historical median of 22.44. Over the past decade, Neuland Laboratories' Cyclically Adjusted PB Ratio has ranged from 15.69 to 24.93. According to the industry distribution chart, Neuland Laboratories ranks #741 out of 759 companies in the Drug Manufacturers industry, placing it in the top 97.6%.
Is Neuland Laboratories' Cyclically Adjusted PB Ratio too high?
Neuland Laboratories' current Cyclically Adjusted PB Ratio of 23.97 is near median its 10-year median of 22.44. Over the past 10 years, this metric has ranged from a low of 15.69 to a high of 24.93. The Drug Manufacturers industry median Cyclically Adjusted PB Ratio is 1.82. Neuland Laboratories' value of 23.97 is 1217% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #741 out of 759 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neuland Laboratories has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Cyclically Adjusted PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #741 out of 759 companies for Cyclically Adjusted PB Ratio. This places Neuland Laboratories in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.82. Neuland Laboratories' value of 23.97 is 1217% above this benchmark. Historically, Neuland Laboratories' own Cyclically Adjusted PB Ratio has ranged from 15.69 to 24.93 over the past decade. While the company's 10-year median is 22.44 vs. the industry median of 1.82, Neuland Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PB Ratio among Drug Manufacturers companies is 1.82, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current Cyclically Adjusted PB Ratio of 23.97 is 1217% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PB Ratio is 1.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current Cyclically Adjusted PB Ratio is 23.97, which is near median its own 10-year median of 22.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,059.40, compared to a current price of ₹19,019.00 — trading 18.4% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 23.97, which is near median its 10-year median of 22.44 and 1217% above the Drug Manufacturers industry median of 1.82. Neuland Laboratories' overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Cyclically Adjusted PB Ratio is 23.97 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹19,019.00 is trading 18.4% above its estimated GF Value™ of ₹16,059.40.
GuruFocus considers Neuland Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
Cyclically Adjusted PB Ratio: 23.97 (near median its 10-year median of 22.44)
GF Value™: ₹16,059.40 vs. price of ₹19,019.00 (18.4% above fair value)
Industry Position: 1217% above the Drug Manufacturers median (#741 of 759)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
91GF Score
Get the complete analysis for NSE:NEULANDLAB
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
